ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
May 1, 2019 4:13 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $62.96 million versus the consensus estimate of $60.69 million.
GUIDANCE:
Acadia Pharma sees FY2019 revenue of $280-300 million, versus the consensus of... More



